Alexandria Real Estate Equities, Inc. (ARE) announced a quarterly cash dividend of $1.30 per common share for the third quarter of 2024, representing an increase of 5% over the previous year. This dividend reflects the company’s strong financial performance and commitment to shareholder value. ARE expects to generate $2.1 billion for reinvestment over the next five years.
Bio-Rad Laboratories, Inc. is facing a challenging environment with slowing growth in its Life Science segment due to a soft Biopharma market and macroeconomic headwinds. While the company is optimistic about the future of its Droplet Digital PCR (ddPCR) technology, it has lowered its adjusted operating margin projection for 2024 due to increased costs and competitive pressure. Despite these challenges, Bio-Rad continues to invest in its Clinical Diagnostics segment, which saw growth in the second quarter.
